Andreas Eckert will later move into the Supervisory Board. His family office holds about one-third of the shares in Eckert & Ziegler AG and rights to appoint members of that body. Before moving to the Supervisory Board, he intends to finish a number of projects under the framework of a consulting agreement.
Lutz Helmke, who is leaving the Executive Board at his own request under an early retirement scheme, will, together with Harald Hasselmann, remain Managing Director of the subsidiary Eckert & Ziegler Radiopharma GmbH. He will focus on the development of actinium production in Dresden-Rossendorf.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
http://www.ezag.de
Öffentlichkeitsarbeit
Telefon: +49 (30) 941084-138
Fax: +49 (30) 941084-112
E-Mail: karolin.riehle@ezag.de
